TTrialPathMatch Me to Trials
← Back to trials
RecruitingGlaucoma

Topical Insulin for Glaucoma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Sponsor: Stanford University

You may qualify if…

  • ✓ Capable to provide informed consent
  • ✓ Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.
  • ✓ Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.

You may not qualify if…

  • ✕ Pregnant or breastfeeding woman
  • ✕ Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)
  • ✕ Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus
  • ✕ Inability to perform reliable visual field
  • ✕ Unable to provide informed consent
  • ✕ Unable to complete the tests and follow-ups required by the study

Where it's recruiting

California

Palo Alto

Source: ClinicalTrials.gov · NCT05206877 · last updated 2026-10-20